Science & technology
An LFA detects a specific analyte — small molecule, protein, pathogen, or nucleic acid — in a sample such as urine, blood, saliva, or food matrix. A labelled antibody conjugated to nanoparticles binds the analyte; capillary flow carries the complex to a capture line on a nitrocellulose membrane, producing a visible result in 5–15 minutes. No instruments, cold chain, or trained operator required.
The platform is deceptively simple to use and technically demanding to develop correctly. Consistent performance across real matrices, at defined cut-off concentrations, and in compliance with applicable standards requires expertise that cannot be improvised.
Most LFA concepts are scientifically plausible. The harder question is whether yours survives contact with a real sample matrix, meets the mandated cut-off, and can be manufactured consistently at a viable cost. Results that hold in buffer routinely fail in urine, whole blood, or food homogenates — and that gap is where most projects stall.
The right time to involve a specialist is before you commit to a development path. Antibody selection, quality framework, and validation design are all settled in the first weeks — and the cost of getting them wrong compounds over 18–36 months.
Five decisions made in the first three months determine whether you reach market in 18 months or 4 years: defining your analyte and intended use precisely; establishing your regulatory pathway before development begins; securing appropriate development capability; implementing your QMS before generating data; and designing validation around certification requirements, not convenience.
Getting the architecture right early typically saves 6–12 months of overall timeline. Front-loading decision quality — not capital — is what separates fast programs from slow ones.
ELISA is equilibrium-based and plate-immobilised. LFA is kinetic and flow-based. An antibody with excellent ELISA metrics can fail completely on a strip — because binding kinetics (kon/koff), matrix performance, epitope complementarity, and cross-reactivity profile each matter far more than equilibrium affinity alone.
Antibody selection is the highest-leverage and hardest-to-reverse decision in the early program. Screening against the wrong criteria — or in the wrong conditions — creates problems that no downstream strip optimisation can fix.
Talk to us about antibody strategyTimelines & costs
Simple assay, experienced team: 12–18 months. Novel target, complex matrix: 24–36 months. Infectious disease LFA with ISO 13485 and clinical trials: 3–5 years.
The dominant cause of overruns is not technical failure — it is regulatory requirements discovered after data has already been generated to the wrong protocol. That single mistake routinely adds 6–18 months to a program.
Review your timeline with usIndicative ranges: assay development USD $100k–$325k; QMS implementation USD $50k–$250k; clinical validation USD $75k–$500k+; in-house facility setup USD $350k–$1.5M+. The upper ends of each range are reached by programs that generate rework.
The single largest cost amplifier is rework — repeating development steps because the assay was not designed to the right specification. Expert guidance typically costs a fraction of one round of rework.
Get a realistic budget viewPartners, regulation & IP
The wrong CDO is one of the most expensive mistakes in an LFA program — and the consequences rarely surface at selection. They appear 12–18 months later in failed performance data, slipped timelines, or contested IP.
What matters: demonstrated LFA experience in your specific product category; QMS scope matched to your regulatory pathway; named scientists (not a sales team); explicit IP and data ownership in the contract; documented process transfer capability. Price is rarely the right primary criterion.
Get independent CDO guidanceThe applicable standard is determined by intended use and target market, not by the technology. Veterinary and agricultural LFAs: ISO 9001. Food safety: ISO 9001 ± ISO 22000. Drugs-of-abuse testing: ISO 9001 in Australia (AS/NZS framework), but ISO 13485 in the EU (Annex II IVDR), US (clinical claims), ASEAN, and India (CDSCO). Medical device LFAs: ISO 13485 universally.
The EU–Australia difference on drugs-of-abuse testing is the most common planning failure we see. It is worth confirming your market requirements before committing to a QMS implementation path.
Confirm your regulatory requirementsIP exposure arises at three points. First: freedom-to-operate — specific conjugation chemistries, membrane treatments, and reader algorithms may be protected even though the LFA platform itself is off-patent. Second: formulation know-how — your antibody pairs, conjugation conditions, and buffer chemistry are typically trade secret, protected through NDAs and access controls, not patent. Third: CDO and supplier contracts — standard agreement language often favours the counterparty on data ownership and improvement rights.
Have any development or supply agreement reviewed by a specialist IP lawyer before signing. The cost is small relative to the exposure.
Discuss IP protectionTroubleshooting & working with us
LFA failure traces to a small set of root causes: antibody–matrix mismatch; conjugate characterised in solution rather than on the strip; component variability (membrane lot, pad interactions, humidity); unmanaged scale-up; or an assay designed to the wrong specification from the start.
All five are diagnosable. A structured root cause review — covering development history, raw data, stability records, and prior certification submissions — almost always identifies the failure mode faster and cheaper than continued ad hoc troubleshooting.
Both are viable. Outsourcing means lower upfront capital and faster access to expertise — suited to companies whose core business is commercialisation, not manufacturing. Building in-house gives greater process control and is essential for long-term in-house manufacture, but requires significant investment in equipment, GMP infrastructure, and staff.
The most capital-efficient path for many companies is a hybrid: external specialist support through early development and prototype validation, then a planned transition to in-house capability. Structuring that transition correctly is part of the program design — not an afterthought.
Talk through the optionsLateralSys is a specialist consultancy, not a CDO or manufacturer. We provide technical and regulatory expertise to advance, troubleshoot, or rescue your LFA program — working alongside your team, not instead of it.
Engagements take three forms: concept and feasibility review (before capital is committed); development program guidance (ongoing advisory through an active program); or diagnostic review and rescue (root cause analysis and remediation for a failing assay). Every engagement starts with a no-obligation 30-minute conversation.
Book a 30-minute callUsually improved. Most underperforming LFAs have a localised failure mode — a conjugate never optimised for strip conditions, a blocking strategy generating non-specific background, membrane lot drift, or a validation dataset collected inconsistently with the applicable standard. These are correctable without starting over.
Redevelopment is only genuinely required when the antibody pair is fundamentally mismatched, the assay was designed to the wrong cut-off with no path to correction, or quality records are unrecoverable. A structured diagnostic review can distinguish between the two paths quickly — and is always worth doing before committing to either.
Get an assessmentA no-obligation 30-minute diagnostic conversation — at any stage of your program. Most problems are identifiable early, even when resolving them takes longer.